慢性髓性白血病:2022年诊断、治疗和监测更新
该综述概述了慢性髓性白血病(CML)的疾病特征、诊断标志(t(9;22)易位及BCR::ABL1融合基因)、一线酪氨酸激酶抑制剂(TKI)治疗(伊马替尼、达沙替尼、博舒替尼、尼洛替尼)以及挽救治疗策略,包括二代/三代TKI和异基因造血干细胞移植。
要点
- CML以t(9;22)(q34;q11.2)易位形成的费城染色体及BCR::ABL1融合基因为特征。
- 美国FDA批准伊马替尼、达沙替尼、博舒替尼和尼洛替尼用于初诊慢性期CML的一线治疗。
- T315I“看门人”突变患者对除帕纳替尼、阿西米尼和奥雷巴替尼外的所有可用TKI耐药。
核心结论
- 二代TKI较伊马替尼可获得更深更快的治疗反应,但未延长生存期,可能与一线TKI细胞遗传学失败后有效TKI挽救治疗的可及性有关。
- 对至少两种TKI耐药或不耐受的慢性期CML患者及所有进展期患者,异基因造血干细胞移植仍是重要治疗选择。
- 对所有TKI失败后出现细胞遗传学复发的老年患者,如继续每日使用最有效/毒性最低的TKI,联合或不联合非TKI抗CML药物,可维持长期生存。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- CML为骨髓增殖性肿瘤,成人年发病率约1-2例/10万,约占成人新诊断白血病的15%。
- 二代TKI临床试验报告了显著更深更快的治疗反应,但未延长生存期。
- T315I“看门人”突变患者对除帕纳替尼、阿西米尼和奥雷巴替尼外的所有当前可用TKI耐药。
关键数值与推荐
- 美国食品药品监督管理局(FDA)批准伊马替尼、达沙替尼、博舒替尼和尼洛替尼用于初诊慢性期CML的一线治疗。
- 一线TKI治疗失败后的二线选择包括二代和三代TKI。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. DIAGNOSIS: CML is characterized by a balanced genetic translocation, t (9;22) (q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR::ABL1 fusion oncogene, which in turn translates into a BCR::ABL1 oncoprotein. FRONTLINE THERAPY: Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib are approved by the United States Food and Drug Administration for first-line treatment of newly diagnosed CML in chronic phase (CML-CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses but had no impact on survival prolongation, likely because of the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy. SALVAGE THERAPY: For CML post failure on frontline therapy, second-line options include second and third generation TKIs. Although potent and selective, these TKIs exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients' comorbidities, disease stage, and BCR::ABL1 mutational status. Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP and failure (due to resistance) of at least two TKIs, and for all patients in advanced phase disease. Older patients who have a cytogenetic relapse post failure on all TKIs can maintain long-term survival if they continue a daily most effective/least toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan and others).
引用
- Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022. PMID: 35751859. doi:10.1002/ajh.26642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。